STAAR Surgical Company (STAA)
| Previous close | 41.02 |
| Open | 41.31 |
| Bid | 42.85 x 100 |
| Ask | 43.15 x 100 |
| Day's range | 41.31 - 43.30 |
| 52-week range | 26.66 - 67.36 |
| Volume | |
| Avg. volume | 704,818 |
| Market cap | 2.111B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 138.61 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
STAAR Surgical Reports First Quarter 2024 Results
LAKE FOREST, Calif., May 07, 2024--STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.
- Business Wire
STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision
LAKE FOREST, Calif., May 07, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announces another milestone achieved on its U.S. Highway 93 go-to-market program – a strategic agreement with IQ Laser Vision, a leader in providing clear vision to clients with locations across California and Texas, and a top EVO ICL practice in North America.
- Business Wire
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
LAKE FOREST, Calif., May 01, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company’s executive committee and report to Tom Frinzi, STAAR Surgical’s President and CEO.
